- Financing co-led by Andera Partners, New Rhein Healthcare Investors, and Omega Funds, with participation from financial and strategic healthcare investors
- Proceeds to support Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline
- Company led by an experienced management team with deep expertise in metabolic disease drug development and commercialization
Andera Partners, a leading European private equity player, today announced that it is co-leading a $159.8 million Series A round of Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The funding round was led by Andera Partners, New Rhein Healthcare Investors, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare investors.
Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company’s lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.
ALV-100 is a bifunctional fusion protein combining GIP receptor antagonism with GLP-1 receptor agonism, designed to deliver potent and sustained weight loss as well as long-term weight maintenance. Alveus’ early-stage pipeline includes ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist, along with amylin-based small-molecule oral candidates and multifunctional biologic formats.
“Obesity is one of the fastest-growing global healthcare challenges, and today’s therapies leave patients struggling to maintain weight loss over time,” said Raj Kannan, Chief Executive Officer of Alveus. “ALV-100 and our amylin-based pipeline are being developed to deliver durable efficacy with infrequent dosing, improved tolerability, and meaningfully better body-composition outcomes. With world-class investors and a team that has repeatedly brought metabolic medicines from concept to commercialization, Alveus is well positioned to lead the next wave of innovation in obesity therapeutics.”
Jan Van den Bossche, Partner at Andera Partners, added: “This Series A financing underscores our confidence in Alveus’ ability to set new standards of care in obesity and metabolic disease, which aligns with our mission to invest in innovation that makes a lasting difference in patients’ lives. With preclinical and clinical operations anchored in the US and Denmark, Alveus combines global reach with executional excellence. We are proud to back a team that brings deep clinical insight and the ambition to make a meaningful impact on global health while scaling innovation worldwide.”
In conjuction with the financing, Jan Van den Bossche has joined the Alveus Board of Directors.